Based on these findings, a novel potential treatment strategy, the combination of specific CtBP2 protein inhibitor and DNA-PK inhibitors, was proposed to target CtBP2 protein and DNA-PK in platinum-resistant serous ovarian cancer. This evidence concerns the gene PRKDC and ovarian serous adenocarcinoma.